Brief: Dri Healthcare Trust Announces Acquisition Of A Royalty Interest In The Worldwide Sales Of Xenpozyme® (Olipudase Alfa) For The Treatment Of Acid Sphingomyelinase Deficiency

DRI Healthcare Trust

28/11/2022 12:50

Nov 28 (Reuters) - Dri Healthcare Trust  DHT_u.TO :
    * DRI HEALTHCARE TRUST ANNOUNCES ACQUISITION OF A ROYALTY
INTEREST
IN THE WORLDWIDE SALES OF XENPOZYME® (OLIPUDASE ALFA) FOR THE
TREATMENT OF ACID SPHINGOMYELINASE DEFICIENCY
    * DRI HEALTHCARE TRUST - LONG-TERM PATENT-PROTECTED
EXCLUSIVITY
EXTENDS DRI'S CASH FLOWS
    * DRI HEALTHCARE TRUST - ACQUIRED A ROYALTY INTEREST IN
WORLDWIDE
SALES OF XENPOZYME (OLIPUDASE ALFA) FOR A PURCHASE PRICE OF
US$30 MILLION
    * DRI HEALTHCARE TRUST - TRANSACTION ENTITLES DRI TO
ROYALTIES
EQUAL TO APPROXIMATELY ONE PERCENT OF WORLDWIDE NET SALES OF
XENPOZYM
    * DRI HEALTHCARE TRUST - EXPECTS TO RECEIVE ROYALTIES ON NET
SALES
OF XENPOZYME FOR APPROXIMATELY 15 YEARS
    * DRI HEALTHCARE TRUST - FOR SALES MADE IN THIRD AND FOURTH
QUARTERS OF YEAR, DRI EXPECTS TO RECEIVE ITS ROYALTY PAYMENT IN
Q2 OF FOLLOWING YEAR
    * DRI HEALTHCARE TRUST - FOR SALES MADE IN FIRST AND SECOND
QUARTERS OF A YEAR, DRI EXPECTS TO RECEIVE ITS ROYALTY PAYMENT
IN Q4 OF THAT YEAR

Source text for Eikon:  ID:nCNWhflDKa 
Further company coverage:  DHT_u.TO 
 ((Reuters.Briefs@thomsonreuters.com;;))